Donald Vollmer
Geriatric Medicine · Huntsville, ALNPI 1184612921
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,162 of the $229,223 with a category attached, or 72.1%. 14 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 40.2% of the total. Among geriatric medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $598.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$92K
- Acadia Pharmaceuticals Inc$53K
- Sunovion Pharmaceuticals Inc.$31K
- AstraZeneca$14K
- Sumitomo Pharma America, Inc.$13K
- Urovant Sciences Inc$9K
- plus $16K from 8 others
What the payments were for
- Consulting fees$30,88713%
- Speaking & faculty fees$165,16272%
- Travel & lodging$23,11810%
- Food & beverage$10,0534%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 88 | $92,041 |
| Acadia Pharmaceuticals Inc | 97 | $52,796 |
| Sunovion Pharmaceuticals Inc. | 64 | $31,441 |
| AstraZeneca | 32 | $14,322 |
| Sumitomo Pharma America, Inc. | 20 | $13,260 |
| Urovant Sciences Inc | 21 | $9,089 |
| Otsuka America Pharmaceutical, Inc. | 20 | $7,566 |
| Novartis | 18 | $6,846 |
| UCB, Inc. | 3 | $793 |
| SK Life Science, Inc. | 11 | $573 |
| Avanir Pharmaceuticals, Inc. | 6 | $289 |
| AbbVie | 1 | $125 |
| Neurelis, Inc. | 1 | $48 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$229,223 in reported general payments places this provider in the 95th percentile of 39 geriatric medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 5,383 | $973,982 |
| NuplazidPimavanserin Tartrate | 382 | $741,044 |
| IngrezzaValbenazine Tosylate | 89 | $619,476 |
| AustedoDeutetrabenazine | 80 | $320,540 |
| Invega SustennaPaliperidone Palmitate | 65 | $217,470 |
| XareltoRivaroxaban | 1,134 | $215,825 |
| AptiomEslicarbazepine Acetate | 310 | $191,047 |
| JanuviaSitagliptin Phosphate | 1,034 | $185,260 |
| EntrestoSacubitril/Valsartan | 865 | $180,661 |
| OzempicSemaglutide | 148 | $153,270 |
| GemtesaVibegron | 768 | $121,967 |
| LinzessLinaclotide | 204 | $116,738 |
| Divalproex Sodium | 5,264 | $113,136 |
| NuedextaDextromethorphan Hbr/Quinidine | 266 | $112,350 |
| JardianceEmpagliflozin | 566 | $106,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $52,796 | $741,044382 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $92,041 | $619,47689 claims |
| AbbVieLinzess, Vraylar, Creon | $125 | $226,833354 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $31,441 | $191,047310 claims |
| NovartisEntresto | $6,846 | $180,661865 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $13,260 | $121,967768 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $289 | $112,350266 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $14,322 | $86,711275 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 geriatric medicine providers in Alabama.
Other geriatric medicine in Huntsville
- Rodney HolladayHuntsville$80
- Laura DyerHuntsville$73
- Linnea PepperHuntsville$0
- Arden AylorTalladega$5K
- Joel BolenMontgomery$4K
- Ali AhmedBirmingham$3K
- Russell UlrichPiedmont$2K
- Juanita HeersinkDothan$2K
- David RaderMountain Brk$2K
- Igor BidikovHeflin$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.